GAS7 Deficiency Promotes Metastasis in MYCN-Driven Neuroblastoma

Zhiwei Dong1, Kok Siong Yeo1, Gonzalo Lopez2

  • 1Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Mayo Clinic Cancer Center, Rochester, Minnesota.

Cancer Research
|February 19, 2021
PubMed

Insights

Growth arrest-specific 7 (GAS7) gene deletion or repression accelerates neuroblastoma metastasis. GAS7 deficiency in MYCN-driven tumors impairs cell-cell adhesion and increases MYCN protein levels, promoting tumor spread.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Neuroblastoma metastasis is a major challenge in curative treatment.
  • MYCN oncogene amplification drives aggressive neuroblastoma.
  • Limited understanding of regulatory proteins in MYCN-mediated metastasis.

Purpose of the Study:

  • Investigate the role of the GAS7 gene in MYCN-driven neuroblastoma metastasis.
  • Elucidate the mechanism by which GAS7 influences tumor cell behavior and spread.

Main Methods:

  • Analysis of gene deletion and expression in neuroblastoma patient samples.
  • Utilized zebrafish and mammalian models for in vivo studies.
  • Examined gene expression profiles and tumor ultrastructure.

Main Results:

  • GAS7 is preferentially deleted or downregulated in high-risk, MYCN-amplified neuroblastoma.
  • GAS7 deficiency accelerates metastasis in preclinical models.
  • GAS7 loss leads to reduced cell-cell adhesion and increased MYCN protein levels.

Conclusions:

  • GAS7 acts as a tumor suppressor by inhibiting cell dispersion.
  • GAS7 depletion is a critical early event in MYCN-driven neuroblastoma metastasis.
  • Targeting GAS7 or its pathway may offer new therapeutic strategies.